INmune Bio Inc. (INMB)
NASDAQ: INMBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
INMB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $25.60M
- EPS (TTM)
- -$0.60
- Dividend yield
- None
- 52-week range
- 0.8189 – 2.60
- Day range
- 0.8189 – 0.9166
- Volume / Avg
- 326.63K / 338.47K
- Beta
- —
- Shares outstanding
- 30.96M
52-week range
INMB stock today
INmune Bio (INMB) closed at $0.827 on Nov 20, down 7.50% (-$0.0671), versus the S&P 500's 3.70% decline. At this level, INMB sits near the bottom of its 52-week range of $0.8189 to $2.60: 68.2% below the high, set on Sep 8, 2026 and 1.0% above the low. INMB is down 47.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.2%.
INmune Bio has posted a net loss over the last twelve months (EPS of -$0.60), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About INmune Bio
Company profileINmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. David J. Moss M.B.A.
- Headquarters
- Boca Raton, FL
- Employees
- 21
- IPO year
- 2019
- Website
- inmunebio.com
Financial highlights
Full financialsIn fiscal 2025, INmune Bio generated $50,000 in revenue, up 257.1% from fiscal 2024. INmune Bio reported a net loss of $45.9 million, compared with a loss of $42.1 million a year earlier. Operating margin was -94766.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $50.00K | $14.00K | $155.00K | $374.00K | $181.00K |
| Growth | +257.14% | -90.97% | -58.56% | +106.63% | +1545.45% |
| Net income | $-45.93M | $-42.08M | $-30.01M | $-27.30M | $-30.34M |
| EPS (diluted) | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$7.00+746.43%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.24 vs —
INMB news
All INMB news- INmune Bio (INMB) Q3 2026 Earnings Call TranscriptNasdaq
- INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5thGlobeNewswire
- INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewswire
- INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027GlobeNewswire
- INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™GlobeNewswireINMB, QUBT
- Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key GoalNasdaqABBV, AZN, CMMB, GMAB
INmune Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PTHSPelthos Therapeutics Inc. | 6.38 | -8.73% | $25.08M | vs INMB |
| LONALeonaBio Inc. | 2.02 | -17.89% | $26.41M | vs INMB |
| SAENGenenta Science S.p.A. ADR | 0.5074 | -9.39% | $24.47M | vs INMB |
| EXOZeXoZymes Inc. | 2.91 | -14.05% | $27.42M | vs INMB |
| MGXMetagenomi Therapeutics Inc. | 0.565 | -7.95% | $21.36M | vs INMB |
| CVMCel-Sci Corporation | 1.21 | -17.69% | $21.28M | vs INMB |
| EVAXEvaxion A/S ADR | 2.25 | +10.84% | $20.75M | vs INMB |
| KLRSKalaris Therapeutics Inc. | 1.28 | -5.19% | $30.47M | vs INMB |
Indexes, lists and sector
INmune Bio stock FAQ
What is INmune Bio's stock price today?
INMB last traded at $0.827 as of Nov 20, 4:00 PM EST, down 7.50% on the day. Prices are delayed at least 15 minutes.
Who is INmune Bio's CEO?
Mr. David J. Moss M.B.A. is the chief executive officer of INmune Bio Inc., which has about 21 employees.
What is the INMB 52-week high?
The 52-week high for INMB is $2.60 and the 52-week low is $0.8189. The stock is currently 68.2% below its high.